Expression and clinical significance of BANCR in pancreatic cancer tissues and peripheral blood

doi:10.3877/cma.j.issn.1674-3946.2025.05.006

Abstract

Abstract:

Objective

This study aimed to explore the expression of BRAF-activated non-protein coding RNA (BANCR) in pancreatic cancer tissues and blood, and evaluate its potential as a biomarker for lymph node metastasis and prognosis.

Methods

Clinical data of 68 patients with pancreatic cancer who underwent radical surgery were retrospectively analyzed. Real-time fluorescent quantitative polymerase chain reaction (qRT-PCR) was used to detect BANCR expression levels in paired tumor tissues, adjacent normal pancreatic tissues, and serum samples. Microlymphatic vessel density (MLVD) in tumor tissues was evaluated by immunofluorescence. Paired sample t test was used for statistical analysis to compare differences between pancreatic cancer tissues and adjacent tissues, independent sample t test for differences between LNM(+) and LNM(-) groups, Spearman correlation analysis to assess the correlation between BANCR and MLVD, ROC curve analysis for diagnostic efficacy, and Kaplan-Meier method for survival analysis.

Results

BANCR expression in tumor tissues was significantly higher than that in adjacent normal tissues, and was positively correlated with lymph node metastasis. Peripheral blood BANCR levels were significantly elevated in patients with lymph node metastasis. Preoperative high expression of peripheral blood BANCR showed stronger predictive efficacy for poor prognosis than CA199.

Conclusion

Peripheral blood BANCR expression in pancreatic cancer patients with lymph node metastasis is significantly higher than that in patients without metastasis, suggesting that BANCR may serve as a novel biomarker for predicting lymph node metastasis and evaluating prognosis in pancreatic cancer.

Key words: Pancreatic Neoplasms, Braf-Activated Non-Protein Coding Rna (BANCR), Tumor Tissue, Peripheral Blood

Haitao Sun, Lang Ji, Shaolong Hao, Yang Hu, Hao Sun, Yu Ji, Fang Nie, Wei Han. Expression and clinical significance of BANCR in pancreatic cancer tissues and peripheral blood[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(05): 496-500.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhpwkssxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3946.2025.05.006

https://zhpwkssxzz.cma-cmc.com.cn/EN/Y2025/V19/I05/496

Figures/Tables 7

References 19

[1]	Loveday BPT, Lipton L, Thomson BN. Pancreatic cancer: An update on diagnosis and management[J]. Aust J Gen Pract, 2019. 48(12): 826-831.
[2]	Cohen JD, JavedAA, Thoburn C, et al. Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers[J]. Proc Natl Acad Sci USA, 2017, 114(38): 10202-10207.
[3]	Zhang L, Sanagapalli S, Stoita A. Challenges in diagnosis of pancreatic cancer[J]. World J Gastroenterol, 2018, 24(19): 2047-2060.
[4]	Kong L, Liu P, Zheng M, et al. The miR-1224-5p/ELF3 Axis Regulates Malignant Behaviors of Pancreatic Cancer via PI3K/AKT/Notch Signaling Pathways[J]. Onco Targets Ther, 2020, 13: 3449-3466.
[5]	中华医学会外科学分会胰腺外科学组，中国胰腺癌诊治指南（2021）[J]. 中华外科杂志，2021, 59(07): 561-577.
[6]	Chari ST, Sharma A, Maitra A. Early Detection of Sporadic Pancreatic Ductal Adenocarcinoma: Problems, Promise, and Prospects [J]. Ann Intern Med, 2020, 172(8): 558-559.
[7]	Duran H, Olivares S, Ielpo B, et al. Prognostic Value of Lymph Node Status for Actual Long-Term Survival in Resected Pancreatic Cancer [J]. Surg Technol Int, 2020, 37: 79-84.
[8]	Coppola A, La Vaccara V, Fiore M, et al. CA19. 9 Serum Level Predicts Lymph-Nodes Status in Resectable Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis[J]. Front Oncol, 2021, 11: 690580.
[9]	Ni XG, Bai XF, Mao YL, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer [J]. Eur J Surg Oncol, 2005, 31(2): 164-169.
[10]	Hadano N, Murakami Y, Uemura K, et al. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer [J]. Br J Cancer, 2016, 115(1): 59-65.
[11]	Flockhart RJ, Webster DE, Qu K, et al. BRAFV600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration [J]. Genome Res, 2012, 22(6): 1006-1014.
[12]	Ma S, Yang D, Liu Y, et al. LncRNA BANCR promotes tumorigenesis and enhances adriamycin resistance in colorectal cancer [J]. Aging (Albany NY), 2018, 10(8): 2062-2078.
[13]	Yu X, Zheng H, Chan MT, et al. BANCR: a cancer-related long non-coding RNA [J]. Am J Cancer Res, 2017, 7(9): 1779-1787.
[14]	Wu W, iu X, Wei L, et al. Tp53 Mutation Inhibits Ubiquitination and Degradation of WISP1 via Down-Regulation of Siah1 in Pancreatic Carcinogenesis [J]. Front Pharmacol, 2018, 9: 857.
[15]	Hussen BM, Azimi T, Abak A, et al. Role of lncRNA BANCR in Human Cancers: An Updated Review[J]. Front Cell Dev Biol, 2021, 9: 689992.
[16]	Charles Richard, J, L, Eichhorn PJA. Platforms for Investigating LncRNA Functions [J]. SLAS Technol, 2018, 23(6): 493-506.
[17]	Ferre F, Colantoni A, Helmer-Citterich M. Revealing protein-lncRNA interaction [J]. Brief Bioinform, 2016, 17(1): 106-116.
[18]	Yin F, Saad M, Xie H, et al. Validation of American Joint Committee on Cancer 8(th) edition of TNM staging in resected distal pancreatic cancer [J]. World J Gastrointest Pharmacol Ther, 2020, 11(2): 25-39.
[19]	Wu X, Xia T, Cao M, et al. LncRNA BANCR Promotes Pancreatic Cancer Tumorigenesis via Modulating MiR-195-5p/Wnt/beta-Catenin Signaling Pathway[J]. Technol Cancer Res Treat, 2019, 18: 1533033819887962.

基因名称	方向	5’-3’序列
GAPDH	正向	TCAAGAAGGTGGTGAAGCAGG
GAPDH	反向	TCAAAGGTGGAGGAGTGGGT
BANCR	正向	GAGCCTTGCCAGTTCCATTT
BANCR	反向	TGCAGAGGTGAGATTCAGGT

基因名称	方向	5’-3’序列
GAPDH	正向	TCAAGAAGGTGGTGAAGCAGG
GAPDH	反向	TCAAAGGTGGAGGAGTGGGT
BANCR	正向	GAGCCTTGCCAGTTCCATTT
BANCR	反向	TGCAGAGGTGAGATTCAGGT

变量	例（%）	肿瘤组织	P值	外周血	P值
年龄（岁，±s）^a			0.298		0.109
≤60	21（30.9）	2.87±1.86		1.37±0.91
>60	47（69.1）	3.41±2.17		1.80±1.24
性别（例）^a			0.776		0.486
女	20（29.4）	3.12±2.48		1.50±1.29
男	48（70.6）	3.30±1.91		1.74±1.11
肿瘤大小（cm，±s）^b			0.450		0.258
≤2.0	31（45.6）	2.96±1.93		1.53±0.85
>2.0且≤4.0	15（22.1）	3.17±2.29		1.46±0.89
>4.0	22（32.3）	3.69±2.16		2.00±1.60
淋巴结转移（例）^a			0.064		<0.001
是	39（57.4）	3.66±1.86		2.11±1.32
否	29（42.6）	2.69±2.26		1.08±0.50
远处转移（例）^a			0.294		0.232
是	5（7.4）	5.04±3.58		2.79±1.92
否	63（92.6）	3.10±1.89		1.58±1.06
血管侵犯（例）^a			0.307		0.109
是	22（32.4）	3.65±2.35		2.08±1.64
否	46（67.6）	3.05±1.93		1.47±0.80
生存时间（月，±s）^a			0.784		0.027
≤36	60（88.2）	3.28±1.96		1.75±1.20
>36	8（11.8）	2.97±3.00		1.10±0.61

变量	例（%）	肿瘤组织	P值	外周血	P值
年龄（岁，±s）^a			0.298		0.109
≤60	21（30.9）	2.87±1.86		1.37±0.91
>60	47（69.1）	3.41±2.17		1.80±1.24
性别（例）^a			0.776		0.486
女	20（29.4）	3.12±2.48		1.50±1.29
男	48（70.6）	3.30±1.91		1.74±1.11
肿瘤大小（cm，±s）^b			0.450		0.258
≤2.0	31（45.6）	2.96±1.93		1.53±0.85
>2.0且≤4.0	15（22.1）	3.17±2.29		1.46±0.89
>4.0	22（32.3）	3.69±2.16		2.00±1.60
淋巴结转移（例）^a			0.064		<0.001
是	39（57.4）	3.66±1.86		2.11±1.32
否	29（42.6）	2.69±2.26		1.08±0.50
远处转移（例）^a			0.294		0.232
是	5（7.4）	5.04±3.58		2.79±1.92
否	63（92.6）	3.10±1.89		1.58±1.06
血管侵犯（例）^a			0.307		0.109
是	22（32.4）	3.65±2.35		2.08±1.64
否	46（67.6）	3.05±1.93		1.47±0.80
生存时间（月，±s）^a			0.784		0.027
≤36	60（88.2）	3.28±1.96		1.75±1.20
>36	8（11.8）	2.97±3.00		1.10±0.61

Please choose a citation manager

Content to export